Severe Hypoglycemia clinical trials

Explore recruiting severe hypoglycemia clinical trials.

Recruiting severe hypoglycemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Hypoglycemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia

Norway, Netherlands, Germany, France, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

(21839) A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes.

Italy, France, Netherlands, Belgium, Spain, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.

Italy

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes

Romania, Germany, Belgium, France

Therapeutic use (Phase IV) EU CTIS Study details

Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controlled, investigator-initiated trial

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the effect and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a low residual β-cell function at baseline.

Belgium, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Severe Hypoglycemia trials by city

Severe Hypoglycemia in Toronto Severe Hypoglycemia in Vancouver Severe Hypoglycemia in Montreal Severe Hypoglycemia in Calgary Severe Hypoglycemia in Edmonton Severe Hypoglycemia in Ottawa Severe Hypoglycemia in Winnipeg Severe Hypoglycemia in Quebec City Severe Hypoglycemia in Hamilton Severe Hypoglycemia in Kitchener Severe Hypoglycemia in London Severe Hypoglycemia in Halifax Severe Hypoglycemia in New York Severe Hypoglycemia in Los Angeles Severe Hypoglycemia in Chicago Severe Hypoglycemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease